Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.

摘要: Resistance is one limitation of sorafenib in the treatment hepatocellular carcinoma (HCC). Insulin-like growth factor-1 receptor (IGF-1R) involved cancer cell proliferation. To assess potential synergistic antitumor effects picropodophyllin (PPP), an IGF-1R inhibitor, HLF and PLC/PRL/5, HCC cells were treated with PPP alone or combination sorafenib, a multikinase inhibitor. Normal human umbilical vein endothelial (HUVECs) also used to analyze antiangiogenic drugs. HUVECs cultured on 96-well plates, then PPP, without addition sorafenib. A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt assay hematoxylin eosin staining performed 48 h later. The analyzed using scratch assays after h. proliferation HLF, PLC/PRF/5 HUVEC was suppressed by 0.2 μM 3 more effectively than 10 alone. motility greater extent at that had been exhibited pyknotic nuclei, which characteristic apoptosis. In conclusion, enhanced sorafenib-mediated suppression cells. Therefore, may exert effects.